{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:54Z","timestamp":1772166414217,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2304605"],"award-info":[{"award-number":["2022YFC2304605"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08979-4","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:14:54Z","timestamp":1753787694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Hongyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianshuang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuteng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the EASNMS investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"8","key":"8979_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287. Published Online First: 2016\/02\/24.","journal-title":"JAMA"},{"issue":"8","key":"8979_CR2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552\u201362. https:\/\/doi.org\/10.1007\/s00134-020-06151-x. Published Online First: 2020\/06\/24.","journal-title":"Intensive Care Med"},{"issue":"13","key":"8979_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jama.2017.13836","volume":"318","author":"C Rhee","year":"2017","unstructured":"Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009\u20132014. JAMA. 2017;318(13):1241\u20139. https:\/\/doi.org\/10.1001\/jama.2017.13836. Published Online First: 2017\/09\/14.","journal-title":"JAMA"},{"issue":"11","key":"8979_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1473-3099(17)30322-5","volume":"17","author":"FR Machado","year":"2017","unstructured":"Machado FR, Cavalcanti AB, Bozza FA, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis. 2017;17(11):1180\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(17)30322-5. Published Online First: 2017\/08\/23.","journal-title":"Lancet Infect Dis"},{"key":"8979_CR5","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","volume":"2","author":"S Gando","year":"2016","unstructured":"Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037. https:\/\/doi.org\/10.1038\/nrdp.2016.37. Published Online First: 2016\/06\/03.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"8979_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ccm.2008.06.006","volume":"29","author":"M Levi","year":"2008","unstructured":"Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29(4):627\u201342. https:\/\/doi.org\/10.1016\/j.ccm.2008.06.006. Published Online First: 2008\/10\/29.","journal-title":"Clin Chest Med"},{"issue":"9","key":"8979_CR7","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/01.ccm.0000281468.94108.4b","volume":"35","author":"M Levi","year":"2007","unstructured":"Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191\u20135. https:\/\/doi.org\/10.1097\/01.ccm.0000281468.94108.4b. Published Online First: 2007\/09\/15.","journal-title":"Crit Care Med"},{"key":"8979_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jcrc.2018.11.009[publishedOnlineFirst:20181114]","volume":"50","author":"S Saito","year":"2019","unstructured":"Saito S, Uchino S, Hayakawa M, et al. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2019;50:23\u201330. https:\/\/doi.org\/10.1016\/j.jcrc.2018.11.009[publishedOnlineFirst:20181114]. Published Online First: 20181114.","journal-title":"J Crit Care"},{"issue":"7","key":"8979_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/0885066618773679","volume":"35","author":"T Iba","year":"2020","unstructured":"Iba T, Arakawa M, Di Nisio M, et al. Newly proposed sepsis-induced coagulopathy precedes international society on thrombosis and haemostasis overt-disseminated intravascular coagulation and predicts high mortality. J Intensive Care Med. 2020;35(7):643\u20139. https:\/\/doi.org\/10.1177\/0885066618773679. Published Online First: 2018\/05\/04.","journal-title":"J Intensive Care Med"},{"issue":"5","key":"8979_CR10","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1097\/ALN.0000000000003122","volume":"132","author":"T Iba","year":"2020","unstructured":"Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology. 2020;132(5):1238\u201345. https:\/\/doi.org\/10.1097\/ALN.0000000000003122. Published Online First: 2020\/02\/12.","journal-title":"Anesthesiology"},{"issue":"5","key":"8979_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1254\/fpj.84.417","volume":"84","author":"Y Koshiyama","year":"1984","unstructured":"Koshiyama Y, Ozeki M, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis. Nihon Yakurigaku Zasshi. 1984;84(5):417\u201328.","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"2","key":"8979_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1254\/jjp.41.155","volume":"41","author":"M Iwaki","year":"1986","unstructured":"Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41(2):155\u201362. https:\/\/doi.org\/10.1254\/jjp.41.155. Published Online First: 1986\/06\/01.","journal-title":"Jpn J Pharmacol"},{"issue":"3","key":"8979_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.mat.0000209224.94089.bc","volume":"52","author":"M Miyata","year":"2006","unstructured":"Miyata M, Shirakawa T, Acharya B, et al. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 2006;52(3):272\u20135. https:\/\/doi.org\/10.1097\/01.mat.0000209224.94089.bc. Published Online First: 2006\/06\/09.","journal-title":"ASAIO J"},{"issue":"1","key":"8979_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1527-3466.1995.tb00213.x","volume":"13","author":"K Okajima","year":"1995","unstructured":"Okajima K, Uchiba M, Murakami K. Nafamostat mesilate. Cardiovasc Drug Rev. 1995;13(1):51\u201365.","journal-title":"Cardiovasc Drug Rev"},{"issue":"5","key":"8979_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1526-0968.2003.00088.x","volume":"7","author":"H Nakae","year":"2003","unstructured":"Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial. 2003;7(5):483\u20135. https:\/\/doi.org\/10.1046\/j.1526-0968.2003.00088.x. Published Online First: 2004\/01\/08.","journal-title":"Ther Apher Dial"},{"issue":"11","key":"8979_CR16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1248\/bpb.31.1985","volume":"31","author":"YG Cao","year":"2008","unstructured":"Cao YG, Chen YC, Hao K, et al. An in vivo approach for globally estimating the drug flow between blood and tissue for nafamostat mesilate: the main hydrolysis site determination in human. Biol Pharm Bull. 2008;31(11):1985\u20139. https:\/\/doi.org\/10.1248\/bpb.31.1985. Published Online First: 2008\/11\/05.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"8979_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2133\/dmpk.21.147","volume":"21","author":"S Yamaori","year":"2006","unstructured":"Yamaori S, Fujiyama N, Kushihara M, et al. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet. 2006;21(2):147\u201355. https:\/\/doi.org\/10.2133\/dmpk.21.147. Published Online First: 2006\/05\/17.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"8979_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/MPA.0000000000000310","volume":"44","author":"G Yu","year":"2015","unstructured":"Yu G, Li S, Wan R, et al. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. Pancreas. 2015;44(4):561\u20139. https:\/\/doi.org\/10.1097\/MPA.0000000000000310.","journal-title":"Pancreas"},{"issue":"1","key":"8979_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12876-022-02345-3","volume":"22","author":"JS Kim","year":"2022","unstructured":"Kim JS, Lee SH, Park N, et al. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. BMC Gastroenterol. 2022;22(1):271. https:\/\/doi.org\/10.1186\/s12876-022-02345-3. Published Online First: 20220531.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"8979_CR20","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.gie.2008.10.046","volume":"69","author":"CW Choi","year":"2009","unstructured":"Choi CW, Kang DH, Kim GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009;69(4):e11\u20138. https:\/\/doi.org\/10.1016\/j.gie.2008.10.046.","journal-title":"Gastrointest Endosc"},{"key":"8979_CR21","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. https:\/\/doi.org\/10.1136\/bmj.e7586. Published Online First: 20130108.","journal-title":"BMJ"},{"issue":"1","key":"8979_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13063-023-07853-5","volume":"25","author":"Y Sun","year":"2024","unstructured":"Sun Y, Ding R, Sun H, et al. Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial. Trials. 2024;25(1):4. https:\/\/doi.org\/10.1186\/s13063-023-07853-5.","journal-title":"Trials"},{"issue":"5","key":"8979_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","volume":"18","author":"C Wang","year":"2014","unstructured":"Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014;18(5):563. https:\/\/doi.org\/10.1186\/s13054-014-0563-4. Published Online First: 2014\/10\/17.","journal-title":"Crit Care"},{"issue":"1","key":"8979_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12871-021-01545-w","volume":"22","author":"S Fu","year":"2022","unstructured":"Fu S, Yu S, Wang L, et al. Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis. BMC Anesthesiol. 2022;22(1):28. https:\/\/doi.org\/10.1186\/s12871-021-01545-w. Published Online First: 2022\/01\/23.","journal-title":"BMC Anesthesiol"},{"issue":"4","key":"8979_CR25","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1213\/ANE.0000000000006888","volume":"138","author":"B Williams","year":"2024","unstructured":"Williams B, Zou L, Pittet JF, et al. Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies. Anesth Analg. 2024;138(4):696\u2013711. https:\/\/doi.org\/10.1213\/ANE.0000000000006888. Published Online First: 2024\/02\/07.","journal-title":"Anesth Analg"},{"issue":"11","key":"8979_CR26","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/jth.14578","volume":"17","author":"T Iba","year":"2019","unstructured":"Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989\u201394. https:\/\/doi.org\/10.1111\/jth.14578. Published Online First: 2019\/08\/15.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"8979_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000199638","volume":"40","author":"A Gabryelewicz","year":"1988","unstructured":"Gabryelewicz A, Prokopowicz J, Bodzenta A, et al. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis. Digestion. 1988;40(1):19\u201324. https:\/\/doi.org\/10.1159\/000199638.","journal-title":"Digestion"},{"issue":"4","key":"8979_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1254\/fpj.84.363","volume":"84","author":"M Iwaki","year":"1984","unstructured":"Iwaki M, Ozeki M, Sato T, et al. Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis. Nihon Yakurigaku Zasshi. 1984;84(4):363\u201372.","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"4","key":"8979_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/08941939.2018.1511015","volume":"33","author":"J-S Park","year":"2020","unstructured":"Park J-S, Jeong S, Kim JM, et al. Preventative effect of nafamostat mesilate infusion into the main pancreatic duct on post-ERCP pancreatitis in a porcine model: initial pilot study. J Invest Surg. 2020;33(4):325\u201331. https:\/\/doi.org\/10.1080\/08941939.2018.1511015.","journal-title":"J Invest Surg"},{"issue":"1","key":"8979_CR30","doi-asserted-by":"publisher","first-page":"23012","DOI":"10.1038\/s41598-023-50181-6","volume":"13","author":"K Narumi","year":"2023","unstructured":"Narumi K, Okada T, Lin Y, et al. Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2023;13(1):23012. https:\/\/doi.org\/10.1038\/s41598-023-50181-6. Published Online First: 20231227.","journal-title":"Sci Rep"},{"issue":"2","key":"8979_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/cpt.3118","volume":"115","author":"IL Horvath","year":"2024","unstructured":"Horvath IL, Kleiner D, Nagy R, et al. Nafamostat reduces the incidence of post-ERCP pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2024;115(2):206\u201312. https:\/\/doi.org\/10.1002\/cpt.3118. Published Online First: 20231229.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"8979_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0011-393x(96)80126-3","volume":"57","author":"S Yonekura","year":"1996","unstructured":"Yonekura S, Umeda Y, Ogawa Y, et al. Effects of intermittent nafamostat mesylate in divided doses in patients with disseminated intravascular coagulation occurring with hematopoietic malignancies. Curr Ther Res. 1996;57(3):203\u201314. https:\/\/doi.org\/10.1016\/s0011-393x(96)80126-3.","journal-title":"Curr Ther Res"},{"issue":"1","key":"8979_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40792-024-01926-6","volume":"10","author":"S Tanaka","year":"2024","unstructured":"Tanaka S, Ohmine T. A case of abdominal aortic aneurysm presenting as symptomatic disseminated intravascular coagulation treated with endovascular aneurysm repair and postoperative administration of nafamostat mesylate. Surg Case Rep. 2024;10(1):124. https:\/\/doi.org\/10.1186\/s40792-024-01926-6.","journal-title":"Surg Case Rep"},{"issue":"2","key":"8979_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","volume":"109","author":"D Minakata","year":"2019","unstructured":"Minakata D, Fujiwara SI, Ikeda T, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109(2):141\u20136. https:\/\/doi.org\/10.1007\/s12185-018-02567-w. Published Online First: 20181208.","journal-title":"Int J Hematol"},{"issue":"8","key":"8979_CR35","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/jcm9082629","volume":"9","author":"H Kamijo","year":"2020","unstructured":"Kamijo H, Mochizuki K, Nakamura Y, et al. Nafamostat mesylate improved survival outcomes of sepsis patients who underwent blood purification: a nationwide registry study in Japan. J Clin Med. 2020;9(8):2629. https:\/\/doi.org\/10.3390\/jcm9082629. Published Online First: 2020\/08\/23.","journal-title":"J Clin Med"},{"issue":"6","key":"8979_CR36","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1016\/s0016-5085(18)31253-8","volume":"154","author":"P Plaeke","year":"2018","unstructured":"Plaeke P, De Man J, Hens S, et al. Sa1172 - effects of the non-selective protease inhibitor nafamostat mesylate on intestinal permeability and bacterial translocation in a murine model of sepsis. Gastroenterology. 2018;154(6):S267\u20138. https:\/\/doi.org\/10.1016\/s0016-5085(18)31253-8.","journal-title":"Gastroenterology"},{"issue":"4","key":"8979_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.ta.0000215566.74588.27","volume":"60","author":"T Hryszko","year":"2006","unstructured":"Hryszko T, Inaba K, Ihara H, et al. Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. J Trauma. 2006;60(4):859\u201364. https:\/\/doi.org\/10.1097\/01.ta.0000215566.74588.27. PublishedOnlineFirst:2006\/04\/14.","journal-title":"J Trauma"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08979-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:57:55Z","timestamp":1757314675000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08979-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8979"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08979-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6629099\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has been approved by the Research and Ethics Committee of the First Affiliated Hospital of China Medical University ([2023] No. 453, Shenyang, China). The findings of this study will be shared in peer-reviewed journals and will be presented at conferences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The principal investigators of this trial declare no competing financial or non-financial interests relevant to the conduct or outcomes of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}